Hyperammonemia
Conditions
Brief summary
The aim of the study was to evaluate the tolerability and pharmacokinetic characteristics of TNP-2092 Capsules after single-dose administration in healthy subjects, and the food effect on pharmacokinetics.
Detailed description
This was a single-center, randomized, double-blind, placebo-controlled, dose-ascending single-dose-administration study, and a study on the food effects on pharmacokinetics. Five dose groups of 100 mg, 200 mg, 400 mg, 800 mg, and 1200 mg will be set up. The 100 mg, 200 mg, 800 mg, and 1200 mg groups will complete the single ascending dose study, with 10 subjects randomized in each group, 8 subjects receiving TNP-2092 and 2 receiving placebo. The drug will be administered once in each group in the fasting state, and tolerability will be evaluated on D4. Subjects were sequentially enrolled into different dose groups in ascending order of dose, and only when the previous lower dose was confirmed to be safe and well tolerated could they be enrolled into the next higher dose group. The 400 mg group will complete the single ascending dose study, food effect study and undergo the metabolic transformation evaluation. A total of 18 subjects will be enrolled in the group and randomized into Group A and Group B, with 8 subjects receiving the investigational product and 1 receiving placebo. The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days. In terms of the administration sequence, Group A will first take TNP-2092 Capsules or placebo in the fasting state, and then TNP-2092 Capsules or placebo in the fed state; Group B will first take TNP-2092 Capsules or placebo in the fed state, and then TNP-2092 Capsules or placebo in the fasting state. Tolerability evaluation will be conducted on D4 and at the end of the study of food effects on pharmacokinetics (D8).
Interventions
Administered orally, 100 to 1200 mg
DRUGTNP-2092 placebo capsules
Administered orally
Sponsors
The First Hospital of Jilin University
TenNor Therapeutics (Suzhou) Limited
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Sex: male or female; * Age: 18-45 years, inclusive; * BMI: 19.0-26.0 kg/m2, inclusive; * Female subjects of childbearing potential must agree to practice abstinence or take effective contraceptive measures during the study and at least 70 days (10 weeks) after administration; * Male subjects must agree to practice abstinence or use condoms as a contraceptive measure during the study and at least 70 days (10 weeks) after administration; * Subjects whose clinical laboratory test results are within the normal range or whose test results are abnormal, but judged by the investigator to be of no clinical insignificance; * Those who do not smoke, or have smoked less than 5 cigarettes per day within 3 months before screening; those who do not drink alcohol, or have drunk less than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine) within 6 months before screening; those who have not smoked or drunk alcohol within 48 hours before admission to the study site; * Those who are fully informed of and understand this study, and have signed the Informed Consent Form; * Those who are willing to follow and able to complete all the study procedures.
Exclusion criteria
* Those with symptoms or medical history of cardiovascular, digestive, respiratory, urinary, neurological, blood, immune, endocrine system diseases or tumor, mental illness, or any situation which, in the opinion of the investigator, may threaten the safety of the subjects or affect the correctness of the study results; * Pregnant or lactating women; * Those whose blood pressure above 150/90 mmHg or below 85/55 mmHg (supine position); * Those with regular use of any prescription/over-the-counter drugs, including vitamins, minerals, nutritional supplements or herbs, within 2 weeks before enrollment and during the study; * Those who are HIV positive, syphilis positive, hepatitis B surface antigen positive, hepatitis C antibody positive, and/or with a positive drug urine test result; * Those who have a history of alcohol or drug abuse in the past 10 years; Those with an allergic constitution, a history of allergic diseases or a history of drug allergy; * Those who have had beverages or foods containing methylxanthine (coffee, tea, coke, chocolate and energy drinks), grapefruit (fruit juice) and alcohol within 48 hours (2 days) before the clinical study; * Those who have taken any drug that changes the activity of liver enzymes within 28 days before taking the investigational product or during the study; * Those who have donated blood within 3 months before enrollment; * Those who have participated in any clinical studies within 3 months before enrollment; * Those who are the staff of the study site directly affiliated to this study or are their immediate family members. Immediate family members are defined as spouses, parents, children or siblings, whether related by blood or legally adopted; * Those who are employees of TenNor Therapeutics; * Other circumstances deemed by the investigator to be unsuitable for the subject to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | Up to 8 days after the first dosing. | To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. |
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
| Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
| Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
| Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
| Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
| Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
| Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
| Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
| Terminal Elimination Half-life (T1/2) in Food Effect Study | Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration | Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. |
Countries
China
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| TNP-2092 Capsules 100mg (Fasting) Participants received single oral dose of TNP-2092 capsules 100mg on Day 1 in fasting state. | 8 |
| TNP-2092 Capsules 200mg (Fasting) Participants received single oral dose of TNP-2092 capsules 200mg on Day 1 in fasting state. | 8 |
| TNP-2092 Capsules 400mg - Group A (Fasting-fed) Participants in TNP-2092 capsules 400mg Group A completed single ascending dose study and food effect study.
Participants received oral dose of TNP-2092 capsules 400mg on Day 1 in fasting state, and in fed state on Day 5 with a 4-day wash-out period. | 8 |
| TNP-2092 Capsules 800mg (Fasting) Participants received single oral dose of TNP-2092 capsules 800mg on Day 1 in fasting state. | 8 |
| TNP-2092 Capsules 1200mg (Fasting) Participants received single oral dose of TNP-2092 capsules 1200mg on Day 1 in fasting state. | 8 |
| Placebo (Fasting) Participants received TNP-2092 placebo capsules on Day 1 in fasting state, including 2 participants each in 100, 200, 800, 1200 mg dose group, and 1 participant in 400 mg group A. | 9 |
| TNP-2092 Capsules 400mg - Group B (Fed -Fasting) Participants received single oral dose of TNP-2092 capsules 400mg on Day 1 in fed state, and in fasting state on Day 5 with a 4-day wash-out period. | 8 |
| Placebo (Fed-fasting) Participants received placebo on Day 1 in fed state, and in fasting state on Day 5 with a 4-day wash-out period, including one participant in 400 mg group B. | 1 |
| Total | 58 |
Baseline characteristics
| Characteristic | TNP-2092 Capsules 200mg (Fasting) | TNP-2092 Capsules 400mg - Group A (Fasting-fed) | TNP-2092 Capsules 800mg (Fasting) | TNP-2092 Capsules 1200mg (Fasting) | TNP-2092 Capsules 100mg (Fasting) | Placebo (Fasting) | TNP-2092 Capsules 400mg - Group B (Fed -Fasting) | Placebo (Fed-fasting) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 8 Participants | 8 Participants | 8 Participants | 8 Participants | 8 Participants | 9 Participants | 8 Participants | 1 Participants | 58 Participants |
| Age, Continuous | 33.6 years STANDARD_DEVIATION 7.96 | 29.3 years STANDARD_DEVIATION 5.34 | 28.9 years STANDARD_DEVIATION 10.32 | 25.3 years STANDARD_DEVIATION 5.85 | 29.5 years STANDARD_DEVIATION 9.07 | 28.3 years STANDARD_DEVIATION 8.72 | 24.9 years STANDARD_DEVIATION 5.96 | 19 years STANDARD_DEVIATION 0 | 29.1 years STANDARD_DEVIATION 8.04 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 8 Participants | 8 Participants | 8 Participants | 8 Participants | 8 Participants | 9 Participants | 8 Participants | 1 Participants | 58 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 3 Participants | 4 Participants | 4 Participants | 4 Participants | 2 Participants | 3 Participants | 4 Participants | 0 Participants | 24 Participants |
| Sex: Female, Male Male | 5 Participants | 4 Participants | 4 Participants | 4 Participants | 6 Participants | 6 Participants | 4 Participants | 1 Participants | 34 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 8 | 0 / 16 | 0 / 8 | 0 / 8 | 0 / 10 | 0 / 16 | 0 / 2 |
| other Total, other adverse events | 0 / 8 | 1 / 8 | 2 / 16 | 1 / 8 | 1 / 8 | 1 / 10 | 2 / 16 | 0 / 2 |
| serious Total, serious adverse events | 0 / 8 | 0 / 8 | 0 / 16 | 0 / 8 | 0 / 8 | 0 / 10 | 0 / 16 | 0 / 2 |
Outcome results
Primary
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Population: All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study | 214 h*µg/L | Standard Deviation 91.7 |
| TNP-2092 Capsules 200mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study | 632 h*µg/L | Standard Deviation 349 |
Primary
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Population: All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study | 67.9 h*µg/L | Standard Deviation 29.9 |
| TNP-2092 Capsules 200mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study | 164 h*µg/L | Standard Deviation 65.7 |
| TNP-2092 Capsules 400mg (Fasting ) | Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study | 201 h*µg/L | Standard Deviation 71.4 |
| TNP-2092 Capsules 800mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study | 408 h*µg/L | Standard Deviation 480 |
| TNP-2092 Capsules 1200mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study | 339 h*µg/L | Standard Deviation 176 |
Primary
Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Population: All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study | 211 h*µg/L | Standard Deviation 90.6 |
| TNP-2092 Capsules 200mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study | 628 h*µg/L | Standard Deviation 349 |
Primary
Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Population: All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study | 65.4 h*µg/L | Standard Deviation 28.8 |
| TNP-2092 Capsules 200mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study | 161 h*µg/L | Standard Deviation 65 |
| TNP-2092 Capsules 400mg (Fasting ) | Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study | 197 h*µg/L | Standard Deviation 71 |
| TNP-2092 Capsules 800mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study | 404 h*µg/L | Standard Deviation 478 |
| TNP-2092 Capsules 1200mg (Fasting) | Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study | 335 h*µg/L | Standard Deviation 175 |
Primary
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Population: All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study | 50.2 µg/L | Standard Deviation 25.2 |
| TNP-2092 Capsules 200mg (Fasting) | Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study | 102 µg/L | Standard Deviation 36.6 |
Primary
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Population: All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study | 16.7 µg/L | Standard Deviation 7.8 |
| TNP-2092 Capsules 200mg (Fasting) | Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study | 41.7 µg/L | Standard Deviation 17.9 |
| TNP-2092 Capsules 400mg (Fasting ) | Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study | 48.5 µg/L | Standard Deviation 20.8 |
| TNP-2092 Capsules 800mg (Fasting) | Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study | 97.4 µg/L | Standard Deviation 117 |
| TNP-2092 Capsules 1200mg (Fasting) | Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study | 70.3 µg/L | Standard Deviation 41.2 |
Primary
Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)
To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to 8 days after the first dosing.
Population: All subjects who have received at least one dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 0 Participants |
| TNP-2092 Capsules 200mg (Fasting) | Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 1 Participants |
| TNP-2092 Capsules 400mg (Fasting ) | Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 2 Participants |
| TNP-2092 Capsules 800mg (Fasting) | Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 1 Participants |
| TNP-2092 Capsules 1200mg (Fasting) | Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 1 Participants |
| Placebo (Fasting) | Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 1 Participants |
| TNP-2092 Capsules 400mg - (Fed) | Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 2 Participants |
| Placebo (Fed) | Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 0 Participants |
Primary
Terminal Elimination Half-life (T1/2) in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Population: All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Terminal Elimination Half-life (T1/2) in Food Effect Study | 2.74 h | Standard Deviation 1.24 |
| TNP-2092 Capsules 200mg (Fasting) | Terminal Elimination Half-life (T1/2) in Food Effect Study | 3.69 h | Standard Deviation 0.98 |
Primary
Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study | 2.348 h | Standard Deviation 1.0494 |
| TNP-2092 Capsules 200mg (Fasting) | Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study | 2.778 h | Standard Deviation 1.1949 |
| TNP-2092 Capsules 400mg (Fasting ) | Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study | 2.553 h | Standard Deviation 1.2619 |
| TNP-2092 Capsules 800mg (Fasting) | Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study | 2.819 h | Standard Deviation 0.8444 |
| TNP-2092 Capsules 1200mg (Fasting) | Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study | 3.278 h | Standard Deviation 1.1161 |
Primary
Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Population: All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study | 3.56 h | Standard Deviation 0.89 |
| TNP-2092 Capsules 200mg (Fasting) | Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study | 6.94 h | Standard Deviation 2.72 |
Primary
Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Population: All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TNP-2092 Capsules 100mg (Fasting) | Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study | 3.76 h | Standard Deviation 0.46 |
| TNP-2092 Capsules 200mg (Fasting) | Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study | 3.50 h | Standard Deviation 0.53 |
| TNP-2092 Capsules 400mg (Fasting ) | Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study | 3.50 h | Standard Deviation 1.2 |
| TNP-2092 Capsules 800mg (Fasting) | Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study | 3.75 h | Standard Deviation 1.04 |
| TNP-2092 Capsules 1200mg (Fasting) | Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study | 3.25 h | Standard Deviation 1.17 |